Bavarian Nordic A/S

Bavarian Nordic A/S is a Danish biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's mission is to improve health and save lives through innovative vaccine solutions. Headquartered in Hellerup, Denmark, Bavarian Nordic operates with a global footprint, including manufacturing facilities in Denmark and Switzerland, and R&D facilities in Germany, alongside offices in the USA, Canada, and France.

The company's product portfolio primarily addresses public health preparedness and travel health. It is a key supplier of smallpox and mpox vaccines, marketed as JYNNEOS, IMVAMUNE, and IMVANEX, to governments worldwide. Additionally, Bavarian Nordic offers a range of travel vaccines, including Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, Vaxchora for cholera, Vivotif for typhoid, and the recently launched Vimkunya for chikungunya.

Bavarian Nordic maintains a strong market position as a leading global provider of these specialized vaccines. Paul Chaplin serves as the President and CEO, a role he has held since 2014, though he is slated to step down by the end of 2026 or upon the appointment of a successor. Recent developments include a failed acquisition attempt in July 2025 by private equity firms Permira and Nordic Capital, which did not gain sufficient shareholder support. The company also reported strong financial performance in H1 2025, leading to an upward revision of its full-year guidance, and has been actively engaged in share buy-back programs.